{"id":"over-dose","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Hypotension"},{"rate":"5-10%","effect":"Tachycardia"}]},"_chembl":null,"_fixedAt":"2026-03-30T18:34:33.519113","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Naloxone is a competitive antagonist of the opioid receptor, which means it binds to the same receptors as opioids but does not activate them. This binding action reverses the effects of opioids, including respiratory depression, sedation, and euphoria.","oneSentence":"Naloxone works by binding to opioid receptors in the brain, reversing the effects of opioid overdose.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:59:06.120Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reversal of opioid overdose"}]},"_fixedFields":["pubmed(267)"],"trialDetails":[{"nctId":"NCT04704661","phase":"PHASE1","title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-09","conditions":"Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma","enrollment":51},{"nctId":"NCT01167712","phase":"PHASE3","title":"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-09-27","conditions":"Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma","enrollment":692},{"nctId":"NCT05687123","phase":"PHASE1","title":"Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-08-14","conditions":"Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Neoplasm, Stage III Pancreatic Neuroendocrine Tumor AJCC v8","enrollment":24},{"nctId":"NCT01896999","phase":"PHASE1, PHASE2","title":"Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-03-07","conditions":"Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma","enrollment":146},{"nctId":"NCT04317105","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-17","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":54},{"nctId":"NCT05702853","phase":"PHASE1, PHASE2","title":"Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2023-11-06","conditions":"B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia","enrollment":27},{"nctId":"NCT04310020","phase":"PHASE2","title":"Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-13","conditions":"Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8","enrollment":47},{"nctId":"NCT06223568","phase":"PHASE2","title":"Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-10","conditions":"Squamous Cell Carcinoma of the Head and Neck, Oropharynx, Human Papillomavirus Viruses","enrollment":70},{"nctId":"NCT03798678","phase":"PHASE1","title":"CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-08","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":36},{"nctId":"NCT06982222","phase":"PHASE1","title":"Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-31","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma","enrollment":24},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT03620019","phase":"PHASE2","title":"Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2018-09-10","conditions":"Melanoma Stage Iii, Melanoma Stage Iv, Melanoma","enrollment":25},{"nctId":"NCT07494084","phase":"PHASE4","title":"Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance","status":"NOT_YET_RECRUITING","sponsor":"Washington State University","startDate":"2026-05-01","conditions":"Shift Work Schedule, Circadian Rhythm, Insulin Resistance","enrollment":24},{"nctId":"NCT05564377","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-07","conditions":"Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8","enrollment":2900},{"nctId":"NCT06487481","phase":"PHASE1","title":"Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Adrenocortical Carcinoma (ACC), Recurrent Adrenocortical Carcinoma (ACC), Recurrent Abdominal Adrenocortical Carcinoma (ACC)","enrollment":32},{"nctId":"NCT04847063","phase":"PHASE1","title":"Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-19","conditions":"Peritoneal Mesothelioma, Peritoneal Carcinomatosis, Ovarian Cancer","enrollment":60},{"nctId":"NCT07494149","phase":"NA","title":"Group-Based Exercise Intervention to Prevent Cognitive and Motor Decline","status":"RECRUITING","sponsor":"University of Bergamo","startDate":"2026-02-01","conditions":"Healthy, Older Adults","enrollment":158},{"nctId":"NCT01306019","phase":"PHASE1, PHASE2","title":"Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-09-25","conditions":"X-linked Severe Combined Immunodeficiency (XSCID)","enrollment":40},{"nctId":"NCT07008586","phase":"NA","title":"The Impact of OliPhenolia® Supplementation on Exercise Induced Inflammation and Functional Movement in Humans.","status":"COMPLETED","sponsor":"Anglia Ruskin University","startDate":"2025-07-01","conditions":"Healthy","enrollment":18},{"nctId":"NCT07181941","phase":"PHASE1, PHASE2","title":"Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-03-24","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":30},{"nctId":"NCT05949554","phase":"","title":"Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.","status":"WITHDRAWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-09","conditions":"Neuropathic Pain","enrollment":""},{"nctId":"NCT03752268","phase":"NA","title":"Development of an Intervention to Enhance Cancer Pain Management","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2014-04-15","conditions":"Other Cancer","enrollment":150},{"nctId":"NCT07198074","phase":"PHASE3","title":"Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-01-27","conditions":"Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma","enrollment":255},{"nctId":"NCT06854640","phase":"PHASE1","title":"A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy","status":"RECRUITING","sponsor":"Bayer","startDate":"2025-03-12","conditions":"Sepsis, Coagulopathy","enrollment":36},{"nctId":"NCT03109288","phase":"PHASE1, PHASE2","title":"Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-08-11","conditions":"Multiple Sclerosis","enrollment":250},{"nctId":"NCT07276360","phase":"PHASE2","title":"Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda","status":"RECRUITING","sponsor":"Uganda Cancer Institute","startDate":"2026-03-11","conditions":"Cervical Cancer, Cervix Cancer, Cervical Adenocarcinoma","enrollment":278},{"nctId":"NCT02830724","phase":"PHASE1, PHASE2","title":"Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-06","conditions":"Pancreatic Cancer, Renal Cell Cancer, Breast Cancer","enrollment":124},{"nctId":"NCT02506153","phase":"PHASE3","title":"Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-10","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma","enrollment":1301},{"nctId":"NCT04351256","phase":"PHASE2","title":"Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy","status":"COMPLETED","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2020-05-20","conditions":"NSCLC, Stage III","enrollment":51},{"nctId":"NCT06867068","phase":"PHASE1","title":"Comparison of Two Intravenous Drug Combinations for Ambulatory Oral & Maxillofacial Surgery","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2016-10-04","conditions":"Anesthesia, Tooth Extraction","enrollment":73},{"nctId":"NCT03297606","phase":"PHASE2","title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-03-23","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":720},{"nctId":"NCT01366144","phase":"PHASE1","title":"Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-06-20","conditions":"Breast Carcinoma, Carcinoma of Unknown Primary, Endometrial Carcinoma","enrollment":94},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT04190550","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-04","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","enrollment":24},{"nctId":"NCT06287775","phase":"PHASE1, PHASE2","title":"Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-04-08","conditions":"Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":45},{"nctId":"NCT02621021","phase":"PHASE2","title":"A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-12-04","conditions":"Melanoma","enrollment":170},{"nctId":"NCT07495293","phase":"PHASE1","title":"Ultra-hypofractionated Carbon-ion Therapy for Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2026-03-24","conditions":"Prostate Cancer","enrollment":20},{"nctId":"NCT03328026","phase":"PHASE1, PHASE2","title":"Combination Study of SV-BR-1-GM With Retifanlimab","status":"COMPLETED","sponsor":"BriaCell Therapeutics Corporation","startDate":"2018-03-16","conditions":"Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer","enrollment":36},{"nctId":"NCT05554328","phase":"PHASE2","title":"Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-25","conditions":"Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma","enrollment":165},{"nctId":"NCT04172532","phase":"PHASE1, PHASE2","title":"Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-11","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8","enrollment":92},{"nctId":"NCT07045038","phase":"NA","title":"Blood Flow Restricted Resistance Exercises Versus Low Level Laser on Cardiac Functions in Patients With Chronic Heart Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cairo University","startDate":"2025-01-20","conditions":"Heart Failure NYHA Class II","enrollment":60},{"nctId":"NCT03952585","phase":"PHASE2, PHASE3","title":"De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-09","conditions":"Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":384},{"nctId":"NCT05353439","phase":"PHASE1","title":"Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-07-27","conditions":"Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma","enrollment":18},{"nctId":"NCT06904066","phase":"PHASE1","title":"Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic","enrollment":86},{"nctId":"NCT07498842","phase":"NA","title":"Corticosteroid Tapering in Sarcoidosis","status":"RECRUITING","sponsor":"Royal Brompton & Harefield NHS Foundation Trust","startDate":"2026-03-19","conditions":"Sarcoidosis","enrollment":100},{"nctId":"NCT05627245","phase":"PHASE1","title":"Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-01","conditions":"Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Follicular Lymphoma","enrollment":48},{"nctId":"NCT04034927","phase":"PHASE2","title":"Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-12-04","conditions":"Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor","enrollment":61},{"nctId":"NCT06568172","phase":"PHASE3","title":"Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-02-18","conditions":"Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma, Recurrent Skin Acantholytic Squamous Cell Carcinoma","enrollment":420},{"nctId":"NCT07497438","phase":"PHASE3","title":"Comparison of Two Etoposide Initiation Strategies for Severe Hemophagocytic Lymphohistiocytosis","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-04","conditions":"Hemophagocytic Lymphohistiocytosis","enrollment":176},{"nctId":"NCT07498387","phase":"NA","title":"Management of Catatonic Features in Adolescents With Profound Autism","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tanta University","startDate":"2026-01-01","conditions":"Autism Spectrum Disorder, Catatonia","enrollment":30},{"nctId":"NCT00001309","phase":"PHASE1","title":"The Body's Affect on Vitamin C","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1997-01-23","conditions":"Healthy Volunteers","enrollment":23},{"nctId":"NCT03604978","phase":"PHASE1, PHASE2","title":"Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-17","conditions":"Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma","enrollment":38},{"nctId":"NCT05256225","phase":"PHASE3","title":"Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-16","conditions":"Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma","enrollment":360},{"nctId":"NCT07061977","phase":"PHASE3","title":"Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-11-05","conditions":"Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma","enrollment":336},{"nctId":"NCT05907122","phase":"PHASE3","title":"A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma","status":"COMPLETED","sponsor":"Amgen","startDate":"2023-07-26","conditions":"Melanoma","enrollment":256},{"nctId":"NCT04092283","phase":"PHASE3","title":"Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-04-29","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":660},{"nctId":"NCT06033196","phase":"PHASE2","title":"Tocilizumab in Lung Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-02-13","conditions":"Lung Transplant","enrollment":350},{"nctId":"NCT06360588","phase":"PHASE2","title":"Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-10-08","conditions":"Malignant Solid Neoplasm","enrollment":22},{"nctId":"NCT05554406","phase":"PHASE2","title":"Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-25","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":335},{"nctId":"NCT05019716","phase":"PHASE1, PHASE2","title":"Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-07-13","conditions":"Advanced NUT Carcinoma, Metastatic NUT Carcinoma, Unresectable NUT Carcinoma","enrollment":36},{"nctId":"NCT07285460","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-12-18","conditions":"Hemophilia","enrollment":85},{"nctId":"NCT06418724","phase":"PHASE2","title":"Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Melanoma and Skin Cancer Trials Limited","startDate":"2026-07-30","conditions":"Locally Advanced Cutaneous Squamous Cell Carcinoma","enrollment":27},{"nctId":"NCT06706375","phase":"NA","title":"Compared Reversed US-Guided Dorsal Penile Nerve Block (RUSDPNB) With DPNB in Circumcisions for Pediatric Patients","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2024-11-29","conditions":"Circumcision, Ultrasound, Opioid Consumption","enrollment":216},{"nctId":"NCT04729959","phase":"PHASE2","title":"Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-11","conditions":"Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma","enrollment":59},{"nctId":"NCT02453620","phase":"PHASE1","title":"Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-02-12","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma","enrollment":57},{"nctId":"NCT07437963","phase":"PHASE1, PHASE2","title":"Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-05-01","conditions":"Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma, Refractory Ganglioneuroblastoma","enrollment":76},{"nctId":"NCT07494110","phase":"NA","title":"Aurora: AI-Based Narrative Intervention to Support Emotional Well-Being in Clinical and Non-Clinical Populations","status":"RECRUITING","sponsor":"Universitat Autonoma de Barcelona","startDate":"2026-02-12","conditions":"Institutionalization, Elderly, Mental Health","enrollment":55},{"nctId":"NCT05673200","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-09-25","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":32},{"nctId":"NCT02888743","phase":"PHASE2","title":"Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-08-14","conditions":"Metastatic Colorectal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Colorectal Cancer AJCC v7","enrollment":110},{"nctId":"NCT03775265","phase":"PHASE3","title":"Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-03","conditions":"Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8","enrollment":475},{"nctId":"NCT00644228","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-28","conditions":"DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma","enrollment":525},{"nctId":"NCT04068194","phase":"PHASE1, PHASE2","title":"Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-04-07","conditions":"Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma, Locally Advanced Unresectable Gallbladder Carcinoma","enrollment":103},{"nctId":"NCT04609046","phase":"PHASE1","title":"Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-24","conditions":"Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","enrollment":47},{"nctId":"NCT07328503","phase":"PHASE2","title":"CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Acute Lymphoblastic Leukemia, B-All","enrollment":20},{"nctId":"NCT04236388","phase":"NA","title":"Short Term Ketone Supplementation and Cardiometabolic Health","status":"COMPLETED","sponsor":"Virginia Polytechnic Institute and State University","startDate":"2020-10-02","conditions":"Cardiovascular Risk Factor","enrollment":11},{"nctId":"NCT07475702","phase":"NA","title":"Moon and Sun Brothers: A Community Prevention Intervention (Hermanos de Luna y Sol)","status":"RECRUITING","sponsor":"San Francisco State University","startDate":"2026-01-13","conditions":"Help-Seeking Behavior, Pre-exposure Prophylaxis Use, Condomless Sex","enrollment":360},{"nctId":"NCT06346197","phase":"PHASE3","title":"Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2025-12-08","conditions":"Gastric Cancer, MSI-H, Metastatic Cancer","enrollment":132},{"nctId":"NCT01743950","phase":"PHASE2","title":"A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2012-12-03","conditions":"Glioma","enrollment":49},{"nctId":"NCT06247345","phase":"PHASE1","title":"A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01","status":"SUSPENDED","sponsor":"Alzheimer's Disease Expert Lab (ADEL), Inc.","startDate":"2024-02-06","conditions":"Alzheimer Disease","enrollment":73},{"nctId":"NCT03197506","phase":"PHASE2","title":"Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-01-15","conditions":"Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma","enrollment":52},{"nctId":"NCT07492966","phase":"","title":"Exosomes Effect on Visual Function in CVI","status":"COMPLETED","sponsor":"Hatice Semrin Timlioglu İper","startDate":"2024-06-30","conditions":"Cortical Visual Impairment, Visual Function","enrollment":32},{"nctId":"NCT07270549","phase":"PHASE1, PHASE2","title":"Gene Replacement Therapy for Treatment of Paediatric Patients With CTNNB1 Neurodevelopmental Syndrome","status":"RECRUITING","sponsor":"CTNNB1 Foundation","startDate":"2025-11-01","conditions":"CTNNB1 Neurodevelopmental Syndrome","enrollment":12},{"nctId":"NCT07493538","phase":"PHASE2","title":"MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases","status":"NOT_YET_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2026-08","conditions":"AML, MDS, Acute Leukemia","enrollment":132},{"nctId":"NCT07493317","phase":"PHASE2","title":"Neutralizing Interleukin (IL)-6","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-03","conditions":"Major Depressive Disorder","enrollment":60},{"nctId":"NCT07492355","phase":"PHASE1","title":"TP-3654 Food Effect Study","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2024-03-04","conditions":"Myelofibroses","enrollment":24},{"nctId":"NCT07250048","phase":"PHASE1","title":"A Study in Healthy Men to Find Out How Different Doses of BI 3009947 Are Tolerated and How Different Formulations or Food Influence How BI 3009947 is Taken up Into the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2025-11-21","conditions":"Healthy","enrollment":40},{"nctId":"NCT06877013","phase":"NA","title":"Tolerance Profile of Soluble Fibers in Individuals With Self-perceived GI Sensitivity to Fibers (Tarine)","status":"RECRUITING","sponsor":"Danone Global Research & Innovation Center","startDate":"2025-11-13","conditions":"Population With Self-perceived Gastro-intestinal Sensitivity to Fibers","enrollment":173},{"nctId":"NCT06378528","phase":"EARLY_PHASE1","title":"Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP)","status":"SUSPENDED","sponsor":"University of Wisconsin, Madison","startDate":"2026-09","conditions":"Posttraumatic Stress Disorder","enrollment":5},{"nctId":"NCT06676904","phase":"NA","title":"Neonatal Platelet Transfusion Threshold Trial","status":"RECRUITING","sponsor":"NICHD Neonatal Research Network","startDate":"2025-06-13","conditions":"Thrombocytopenia, Neonatal, Platelet Transfusion","enrollment":2433},{"nctId":"NCT07112183","phase":"PHASE4","title":"Open Label Treprostinil Raynaud's Study","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2025-10-15","conditions":"Raynaud's Disease, Raynaud Phenomena, Raynauds","enrollment":30},{"nctId":"NCT05303532","phase":"PHASE3","title":"Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab","status":"ENROLLING_BY_INVITATION","sponsor":"AstraZeneca","startDate":"2022-04-19","conditions":"Cancer","enrollment":214},{"nctId":"NCT01453088","phase":"PHASE2","title":"Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2010-06-24","conditions":"Multiple Myeloma","enrollment":63},{"nctId":"NCT06337838","phase":"PHASE3","title":"Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial","status":"RECRUITING","sponsor":"Hamilton Health Sciences Corporation","startDate":"2025-06-09","conditions":"Chronic Kidney Diseases, Acute Kidney Injury, Bleeding","enrollment":100},{"nctId":"NCT07089121","phase":"PHASE1, PHASE2","title":"Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders","status":"RECRUITING","sponsor":"Cartesian Therapeutics","startDate":"2026-03-12","conditions":"Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV), Juvenile Myasthenia Gravis","enrollment":50},{"nctId":"NCT06827054","phase":"PHASE2","title":"Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids","status":"NOT_YET_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-05-15","conditions":"Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm","enrollment":20},{"nctId":"NCT05929664","phase":"PHASE2","title":"Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-07-05","conditions":"Locally Advanced Basal Cell Carcinoma, Basal Cell Carcinoma","enrollment":70},{"nctId":"NCT07489729","phase":"NA","title":"Hypo Fractionated Versus Conventional IMRT in Unfavorable Intermediate- and High-Risk Prostate Cancer","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-06-30","conditions":"Hypofractionated Dose, Prostate Cancer Patients","enrollment":60},{"nctId":"NCT07221786","phase":"NA","title":"Preoperative Opioid Tapering Before Spine Surgery","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2025-12-01","conditions":"Opioid Consumption, Postoperative, Pain After Surgery, Opioid Dependency","enrollment":45},{"nctId":"NCT02133196","phase":"PHASE2","title":"T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-10-23","conditions":"Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC","enrollment":85},{"nctId":"NCT03246360","phase":"NA","title":"Pharmacological Comparison of Continuous and Intermittent Infusions of Cloxacillin","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2017-11-23","conditions":"Infection, Methicillin Susceptible Staphylococcus Aureus Infection, Cloxacillin Treatment","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":267,"recentPublications":[{"date":"2026 Mar 20","pmid":"41858245","title":"Therapeutic Gases in Biomedicine: Updates on Nitric Oxide and Beyond.","journal":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)"},{"date":"2026 Feb 25","pmid":"41678958","title":"Feasibility of FLASH radiobiology with proton and carbon ion beams using LINAC4 and Nuclotron accelerators.","journal":"Physics in medicine and biology"},{"date":"2026 Feb 10","pmid":"41622595","title":"Optimizing Cold Atmospheric Plasma Dosage to Enhance DESI-MS Signal Intensity in MDA-MB-231 Breast Cancer Cells: Mechanistic Insights and Workflow Development.","journal":"Analytical chemistry"},{"date":"2026 Jan-Dec","pmid":"41542843","title":"Comment on \"Phase I Randomized, Placebo-Controlled, Cross-Over Dose-Finding Study of Coenzyme Q(10) on Doxorubicin Pharmacokinetics During Breast Cancer Treatment\".","journal":"Integrative cancer therapies"},{"date":"2025 Jan-Dec","pmid":"41261512","title":"Phase I Randomized, Placebo-Controlled, Cross-Over Dose-Finding Study of Coenzyme Q10 on Doxorubicin Pharmacokinetics during Breast Cancer Treatment.","journal":"Integrative cancer therapies"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Domperidone Suspension(Motilium), B12200018238"],"phase":"marketed","status":"active","brandName":"over dose","genericName":"over dose","companyName":"Nanfang Hospital, Southern Medical University","companyId":"nanfang-hospital-southern-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Naloxone works by binding to opioid receptors in the brain, reversing the effects of opioid overdose. Used for Reversal of opioid overdose.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}